Two NPR stories published September 30, 2026 point to the same tension. A non-peer-reviewed HHS report is drawing criticism for challenging accepted standards of care for transgender patients, and potent sedatives are still widely used on agitated people with dementia despite federal efforts to discourage them.

Health note: this article is general information, not medical advice. Decisions about treatment should involve a qualified clinician.

Why put these two stories together?

They look unrelated, but they share a thread: institutions that people rely on for health guidance are being questioned, and in both cases the people affected have little power in the system. One story is about who sets the standard of care for transgender patients. The other is about what happens to some of the most vulnerable older adults in long-term care.

What is the HHS report?

In August 2026, the Department of Health and Human Services released a report on what it called "gender ideology," asking whether it relates to left-wing authoritarian psychology. NPR reported that the paper was not peer reviewed, and that its underlying data and funding have not been made public.

NPR described it as the agency's latest effort to chip away at trust in established health care models for transgender people, and the third recent HHS attempt to reject gender-affirming standards of care. NPR noted that "gender-affirming care" is the accepted medical and mental health standard for treating transgender patients, and that the report uses that term interchangeably with "gender ideology."

What are the objections?

According to NPR, career HHS staff who spoke anonymously said they didn't know about the research before it went public, and one health official criticized its accuracy in strong terms. HHS didn't respond to NPR's requests for comment, and most of the report's authors declined interviews. One co-author, Wright, answered questions by email but insisted on conditions for how the answers could be used, then posted the exchange on his own X account.

The fairest summary is this: the report's supporters see legitimate questions about a contested area. Its critics see a political document dressed as research, one that hasn't gone through the checks scientists normally use. Readers should note that the core complaint is about process, meaning no peer review and no released data, as much as about conclusions.

Why does peer review matter here?

Peer review isn't perfect, but it's the main way science catches mistakes and weak methods before conclusions spread. Without access to the data, other researchers can't replicate the findings or check them. When a government agency publishes work that skips those steps, and that work touches people's medical care, trust becomes the issue.

What's the dementia story?

NPR's investigation found that potent sedating medications, mainly antipsychotic drugs, are often used on agitated people with dementia in long-term care facilities. That's happening even though federal officials have tried to discourage it.

The risk isn't small. The Food and Drug Administration requires drugmakers to warn that these medications raise the risk of death in older people with Alzheimer's and related diseases. More than five million Medicare beneficiaries have a dementia diagnosis, so the scale is large.

What does it look like for a family?

NPR followed the family of Marjorie Tingley, a woman in a dementia care unit at Vista Grande Villa, a Michigan senior living community. After an urgent email in December 2024, her adult sons and the facility argued for months about whether she'd receive an antipsychotic. Hospital records, NPR reported, show the facility said she couldn't return unless the family agreed to sedating medication.

That's the wrenching choice many families describe: consent to a drug they worry about, or risk losing the placement. Some families and guardians do believe the benefits outweigh the risks, and clinicians say medication can sometimes be necessary when someone is in danger. But families with doubts often feel they have little leverage.

Why does this keep happening?

The long-term care industry's reliance on tranquilizing drugs has worried Congress for about fifty years. Staffing is a big part of it. Caring for an agitated person without drugs takes time, training and patience, and many facilities are stretched thin. There's also a legal backdrop: in 2009, Eli Lilly pleaded guilty to allegations that it had improperly promoted its drug Zyprexa for dementia use in long-term care and primary care.

What are the alternatives?

Research on dementia care has long pointed to person-centered approaches: figuring out what triggers distress, such as pain, noise, hunger or boredom; adjusting routines and environments; and training staff in de-escalation. Studies of these approaches have found they can reduce antipsychotic use in nursing homes. They require investment, though, and staff time.

What can families do?

If you have a loved one in long-term care:

  1. Ask what medications are being given and why, and request a written explanation.

  2. Ask about non-drug approaches that have been tried first.

  3. Request a care-plan meeting with the physician, nurses and social worker.

  4. Learn about resident rights. In the U.S., a state long-term care ombudsman can help with disputes, and federal rules require informed consent and limit unnecessary psychotropic drugs.

  5. Document conversations, including dates and names.

None of this guarantees a good outcome, but informed families are harder to overlook.

What ties it all together?

Both stories come down to who holds the power to define good care, and whether the people affected can check the work. In one case, it's whether a government report meets scientific standards. In the other, it's whether a frail person's family can question a prescription without risking eviction. Transparency, independent review and patient voice are the common fixes.

FAQ

What is the HHS "gender ideology" report? An August 2026 report that NPR says was not peer reviewed and whose data and funding haven't been released.

Why are antipsychotics used in dementia care? To calm agitation, though the FDA warns they raise the risk of death in older people with dementia.

How many people are affected? More than 5 million Medicare beneficiaries have a dementia diagnosis.

Where can families get help? A state long-term care ombudsman, the resident's physician and the facility's care-planning team.